Back to News
Market Impact: 0.4
NeurAxis Expands PENFS Coverage By 18 Million Lives As IB-Stim Adoption Grows; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
NeurAxis secured expanded national health-insurer coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) therapy, extending potential access to approximately 18 million additional members. The coverage milestone could materially broaden the addressable reimbursed market for the company’s therapy and support future utilization growth.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
NRXS0.75
More News
- Japan’s corporate leaders sound alarm over weak yen — even dollar-earners are voicing concerns
- Fed hikes again - an AI-Picked insurer is still cashing in
- Berkshire May Boost Japan Trading House Holdings, Itochu Says
- Berkshire may boost holdings in Japan’s trading houses- Bloomberg
- The Competition's Response to Tesla Robotaxi Day
- Generac's stock soars more than 30% after Amazon deal cements its status as AI power player